Head-to-head evidence
Durvalumab vs Envafolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
Durvalumab
Marketed by AstraZeneca and partners
NCT02125461 · Phase 3 · completed
Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251).
Next expected readout: October 2026 · NCT06008093 (registry estimate)
Envafolimab
Developed by Suzhou Alphamab and partners
NCT05068427 · Phase 2 · completed
The study was an open-label, single-arm trial of 34 patients receiving chidamide plus envafolimab, with no randomized control group for comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05024214 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Durvalumab's landscape · Envafolimab's landscape